Timeline: The Hypoallergenic Cat

The Hypoallergenic Cat: A Timeline Feb. 4, 2004 The beginnings of the allergy-free cat. Simon Brodie and David Avner agree on a business plan for using RNAi to knock out the gene for the major cat allergen fel d 1. Sept. 24, 2004 Brodie and Avner agree to form a company called Allerca. Oct. 12, 2004 Brodie backs out of his partnership with Avner. Oct. 26, 2004 Brodie incorporates Allerca without Avner. Oct. 28, 200

Written byKerry Grens
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
The Hypoallergenic Cat: A Timeline
Feb. 4, 2004
The beginnings of the allergy-free cat. Simon Brodie and David Avner agree on a business plan for using RNAi to knock out the gene for the major cat allergen fel d 1.
Sept. 24, 2004
Brodie and Avner agree to form a company called Allerca.
Oct. 12, 2004
Brodie backs out of his partnership with Avner.
Oct. 26, 2004
Brodie incorporates Allerca without Avner.
Oct. 28, 2004
Brodie sends out press releases promising hypoallergenic cats based on RNAi by 2007. "For the first time, people who have been unable to own a cat because of their allergies will be able to have a pet of their own without the associated risks and costs of allergy treatments."
Dec. 14, 2004
Avner sues Brodie for stealing and publicizing his trade secrets, soliciting his customers, and usurping investors, "because it appears, from the public's perspective, that [Allerca has] already 'cornered the market' on this new technology."
Jan. 31, 2005
U.S. District court in Colorado orders an injunction on Allerca "not to reenter the market for genetically engineered allergen-free cats until after 5/31/06."
Jan. 31, 2005
The Scientist publishes "Doubts About Allergy-Free Cats."
Spring 2005
Allerca scientists begin screening cats randomly across the country and in the United Kingdom to try out a fel d 1 genetic test with the intention of developing fel d 1 knockout cats.
Fall 2005
Allerca scientists stumble upon cats with a mutant fel d 1 that renders them hypoallergenic; they determine that the trait is dominant and begin breeding (cat gestation takes 57-69 days; cats reach maturity in 6-10 months).
Spring 2006
Second generation of hypoallergenic cats is born.
May-July 2006
Hired by Allerca, Microbac conducts genetic analysis on samples of hypoallergenic cats and concludes Allerca's cats have mutations not seen in control cats.
May 31, 2006
Injunction is lifted, allowing Allerca to pursue development of allergy-free cats.
June 7, 2006
Allerca announces it has bred hypoallergenic cats and begins accepting deposits.
Sept. 14 2006
In a press release Allerca announces success in independent clinical trials. "This observation exposure shows the Allerca cat has hypoallergenicity."
Fall 2006
Third generation of hypoallergenic cats is born.
Spring 2007
Allerca's scheduled delivery of hypoallergenic cats to customers.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies